Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany

Context Efficacy and safety of once-weekly semaglutide in type 2 diabetes were established in the phase 3 SUSTAIN trials, which included patients across the continuum of type 2 diabetes care. It is useful to complement these findings with real-world evidence. Objective SURE Germany evaluated once-we...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzen, Markus, Berentzen, Tina Landsvig, Catarig, Andrei-Mircea, Pieperhoff, Sebastian, Simon, Jörg, Jacob, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101737/
https://www.ncbi.nlm.nih.gov/pubmed/36599459
http://dx.doi.org/10.1055/a-2007-2061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101737/
https://www.ncbi.nlm.nih.gov/pubmed/36599459
http://dx.doi.org/10.1055/a-2007-2061

Ejemplares similares